 |
|
|
| |
Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in European patients who relapsed after previous interferon-based therapy: the PROMISE trial
|
| |
| |
Reported by Jules Levin
EASL 2014 April 9-13 London, UK
EASL: EASL Coverage: 6 phase 3 studies; Simeprevir+Sofosbuvir Update; HIV Coinfection: 2 studies reported - (04/15/14)
Janssen Initiates Phase 3 OPTIMIST Trials of Once-Daily Simeprevir in Combination with Once-Daily Sofosbuvir for the Treatment of Genotype 1 Chronic Hepatitis C - (04/03/14)
Xavier Forns,1 Eric Lawitz,2 Stefan Zeuzem,3 Edward J Gane,4 Jean Pierre Bronowicki,5 Pietro Andreone,6 Andrzej Horban,7 Ashley S Brown,8 Monika Peeters,9 Oliver Lenz,9 Sivi Ouwerkerk-Mahadevan,10 Guy De La Rosa,11 Ronald Kalmeijer,12 Maria Beumont-Mauviel9
1Liver Unit, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Centro de Investigacion Biomedica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain; 2Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA; 3J.W. Goethe University Hospital, Frankfurt, Germany; 4Auckland Hospital Clinical Studies Unit, Auckland, New Zealand;
5INSERM U954, Universite de Lorraine, Centre Hospitalier Universitaire de Nancy, Vandoeuvre Les Nancy, France; 6Dipartimento di Scienze Mediche e Chirurgiche, University of Bologna, Bologna, Italy; 7Medical University of Warsaw, Wolska, Warsaw, Poland; 8Imperial College Healthcare NHS Trust, London, UK; 9Janssen Infectious Diseases BVBA, Beerse, Belgium; 10Janssen Research & Development, Beerse, Belgium; 11Janssen Global Services, LLC, Titusville, NJ, USA; 12Janssen Research & Development, Titusville, NJ, USA
|
| |
|
|
|
|
|
